Long-term efficacy of formoterol compared to salbutamol View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1990-12

AUTHORS

P. R. Hekking, F. Maesen, A. Greefhorst, J. Prins, Y. Tan, P. Zweers

ABSTRACT

In a randomized, double-blind, between-patient, multicenter study in 301 patients with ROAD, the efficacy and tolerability of the new long-acting selectiveβ2-sympathicomimetic drug formoterol (12µg inhalation b.i.d.) was compared with salbutamol (200µg inhalation q.i.d.). There was no statistically significant (s.s.) difference in acute reversibility and long-term efficacy of both drugs, measured by the point in time of expected maximal effect. However, formoterol had a highly s.s. longer duration of action than salbutamol, as shown by peak expiratory flow (PEF) measurements: the overall mean morning PEF in the formoterol group was 341 L/min.14 h after the last taken dose and in the salbutamol group this measure was 304 L/min9 h after the last dose. The patients taking formoterol had s.s. less asthma attacks and needed s.s. less rescue medication than those taking salbutamol. In the global assessment of efficacy, formoterol was accepted as being s.s. better (“very good” + “good”: 76%) than salbutamol (“very good” + “good”: 50%). The tolerability of each drug, as reflected by adverse reactions and global assessment, was equally good in both groups. Ninety-one percent of the patients in the formoterol group wanted to receive the same drug again versus 79% in the salbutamol group. More... »

PAGES

76-82

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf02718117

DOI

http://dx.doi.org/10.1007/bf02718117

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1012000274

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1974686


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Inhalation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-Agonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Airway Resistance", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Albuterol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asthma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bronchodilator Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Delayed-Action Preparations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ethanolamines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Forced Expiratory Volume", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Formoterol Fumarate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Long-Term Care", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Diseases, Obstructive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multicenter Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peak Expiratory Flow Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.477310.6", 
          "name": [
            "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hekking", 
        "givenName": "P. R.", 
        "id": "sg:person.01217467714.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217467714.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.477310.6", 
          "name": [
            "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maesen", 
        "givenName": "F.", 
        "id": "sg:person.07672177314.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07672177314.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.477310.6", 
          "name": [
            "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Greefhorst", 
        "givenName": "A.", 
        "id": "sg:person.01141121675.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141121675.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.477310.6", 
          "name": [
            "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Prins", 
        "givenName": "J.", 
        "id": "sg:person.0610312214.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610312214.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.477310.6", 
          "name": [
            "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tan", 
        "givenName": "Y.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.477310.6", 
          "name": [
            "Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zweers", 
        "givenName": "P.", 
        "id": "sg:person.01270703304.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270703304.03"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1990-12", 
    "datePublishedReg": "1990-12-01", 
    "description": "In a randomized, double-blind, between-patient, multicenter study in 301 patients with ROAD, the efficacy and tolerability of the new long-acting selective\u03b22-sympathicomimetic drug formoterol (12\u00b5g inhalation b.i.d.) was compared with salbutamol (200\u00b5g inhalation q.i.d.). There was no statistically significant (s.s.) difference in acute reversibility and long-term efficacy of both drugs, measured by the point in time of expected maximal effect. However, formoterol had a highly s.s. longer duration of action than salbutamol, as shown by peak expiratory flow (PEF) measurements: the overall mean morning PEF in the formoterol group was 341 L/min.14 h after the last taken dose and in the salbutamol group this measure was 304 L/min9 h after the last dose. The patients taking formoterol had s.s. less asthma attacks and needed s.s. less rescue medication than those taking salbutamol. In the global assessment of efficacy, formoterol was accepted as being s.s. better (\u201cvery good\u201d + \u201cgood\u201d: 76%) than salbutamol (\u201cvery good\u201d + \u201cgood\u201d: 50%). The tolerability of each drug, as reflected by adverse reactions and global assessment, was equally good in both groups. Ninety-one percent of the patients in the formoterol group wanted to receive the same drug again versus 79% in the salbutamol group.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf02718117", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054004", 
        "issn": [
          "0341-2040", 
          "1432-1750"
        ], 
        "name": "Lung", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "168"
      }
    ], 
    "keywords": [
      "long-term efficacy", 
      "formoterol group", 
      "salbutamol group", 
      "global assessment", 
      "peak expiratory flow measurements", 
      "mean morning PEF", 
      "less rescue medication", 
      "expiratory flow measurements", 
      "acute reversibility", 
      "rescue medication", 
      "morning PEF", 
      "last dose", 
      "multicenter study", 
      "asthma attacks", 
      "adverse reactions", 
      "formoterol", 
      "same drug", 
      "maximal effect", 
      "patients", 
      "salbutamol", 
      "longer duration", 
      "efficacy", 
      "tolerability", 
      "drugs", 
      "significant differences", 
      "dose", 
      "group", 
      "medications", 
      "assessment", 
      "flow measurements", 
      "duration", 
      "percent", 
      "min", 
      "PEF", 
      "differences", 
      "study", 
      "action", 
      "measures", 
      "effect", 
      "time", 
      "reversibility", 
      "attacks", 
      "reaction", 
      "point", 
      "measurements", 
      "road"
    ], 
    "name": "Long-term efficacy of formoterol compared to salbutamol", 
    "pagination": "76-82", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1012000274"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf02718117"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1974686"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf02718117", 
      "https://app.dimensions.ai/details/publication/pub.1012000274"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_253.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf02718117"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf02718117'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf02718117'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf02718117'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf02718117'


 

This table displays all metadata directly associated to this object as RDF triples.

237 TRIPLES      20 PREDICATES      96 URIs      88 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf02718117 schema:about N08875b109dd541d2b01582932e25640c
2 N54184c1bc56b4029a21b190e18564404
3 N5a035d87f6f74290acbbbb72475b5889
4 N6e5f46aa24484b47b63eb2c2cb0ecbd1
5 N7be96e42e4524028a6480acb5acb59c0
6 N80b566a240ea47089a27f0ead5882945
7 N8179a221a3564f21a0c3e216a368edc6
8 N878f486c0851413eaaeb22e611a1bebb
9 N8820be068f384bdf87e4471ff889afd8
10 N8b3be7957f6b4e79a3ba2f69b1d59213
11 N8ecfebae22db46fcacc3e4673c188c84
12 N9bc84b0cdcf74b18a7aff5a741d67959
13 Na0133665a52740479c307d44f30bcec2
14 Na30d297ac51f44c0a86866632607bf19
15 Na3378954ad8d43dab0e38fb1cd1fb262
16 Nadd555e2149540eb82bde041b795025f
17 Nbd2bc7bc603b4feab3b2b91ab04422e2
18 Nc92c7954e9034fe6b023f4d20878e9ee
19 Nd61324b3bad14377900ae4350298ece4
20 Nd665c93701df4a85874fd61670c37d94
21 Nd6e0b80b778b4266bb822773fa15460d
22 Nde76a0531cd24a9b9bbbea222cfab716
23 Nec05093ae9aa49a2b1427f82cf816a24
24 Neea471bfba7746308bd247873ebdb264
25 anzsrc-for:11
26 anzsrc-for:1115
27 schema:author N74d03ab14f5c495a85cd2f1672d5a035
28 schema:datePublished 1990-12
29 schema:datePublishedReg 1990-12-01
30 schema:description In a randomized, double-blind, between-patient, multicenter study in 301 patients with ROAD, the efficacy and tolerability of the new long-acting selectiveβ2-sympathicomimetic drug formoterol (12µg inhalation b.i.d.) was compared with salbutamol (200µg inhalation q.i.d.). There was no statistically significant (s.s.) difference in acute reversibility and long-term efficacy of both drugs, measured by the point in time of expected maximal effect. However, formoterol had a highly s.s. longer duration of action than salbutamol, as shown by peak expiratory flow (PEF) measurements: the overall mean morning PEF in the formoterol group was 341 L/min.14 h after the last taken dose and in the salbutamol group this measure was 304 L/min9 h after the last dose. The patients taking formoterol had s.s. less asthma attacks and needed s.s. less rescue medication than those taking salbutamol. In the global assessment of efficacy, formoterol was accepted as being s.s. better (“very good” + “good”: 76%) than salbutamol (“very good” + “good”: 50%). The tolerability of each drug, as reflected by adverse reactions and global assessment, was equally good in both groups. Ninety-one percent of the patients in the formoterol group wanted to receive the same drug again versus 79% in the salbutamol group.
31 schema:genre article
32 schema:isAccessibleForFree false
33 schema:isPartOf N68a913c0925f4e899aad5deb9ed3a543
34 N9d5eb31faf0346528ef5cc49aaa1a7a2
35 sg:journal.1054004
36 schema:keywords PEF
37 action
38 acute reversibility
39 adverse reactions
40 assessment
41 asthma attacks
42 attacks
43 differences
44 dose
45 drugs
46 duration
47 effect
48 efficacy
49 expiratory flow measurements
50 flow measurements
51 formoterol
52 formoterol group
53 global assessment
54 group
55 last dose
56 less rescue medication
57 long-term efficacy
58 longer duration
59 maximal effect
60 mean morning PEF
61 measurements
62 measures
63 medications
64 min
65 morning PEF
66 multicenter study
67 patients
68 peak expiratory flow measurements
69 percent
70 point
71 reaction
72 rescue medication
73 reversibility
74 road
75 salbutamol
76 salbutamol group
77 same drug
78 significant differences
79 study
80 time
81 tolerability
82 schema:name Long-term efficacy of formoterol compared to salbutamol
83 schema:pagination 76-82
84 schema:productId N09229c867f4a427d9e27c8a2058bf316
85 N18613d9fb3704e0494be8081e578932b
86 Nd5cc577ca5814c6fb8602cf6b37c9cd5
87 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012000274
88 https://doi.org/10.1007/bf02718117
89 schema:sdDatePublished 2022-09-02T15:47
90 schema:sdLicense https://scigraph.springernature.com/explorer/license/
91 schema:sdPublisher Nbd6bb6a01c8e47bf8a3866f08dfab8c9
92 schema:url https://doi.org/10.1007/bf02718117
93 sgo:license sg:explorer/license/
94 sgo:sdDataset articles
95 rdf:type schema:ScholarlyArticle
96 N01ee4be6ada9438ba98c323f7df284af rdf:first N27662ab6e2be4626a463b041c48970ba
97 rdf:rest N6bfe1bea8b424ec29a0c5fd0f6850462
98 N08875b109dd541d2b01582932e25640c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Double-Blind Method
100 rdf:type schema:DefinedTerm
101 N09229c867f4a427d9e27c8a2058bf316 schema:name doi
102 schema:value 10.1007/bf02718117
103 rdf:type schema:PropertyValue
104 N09dc351f08174d029324cd642074155f rdf:first sg:person.07672177314.29
105 rdf:rest Nbf56ef3f24c84aea8b2599acb1124685
106 N18613d9fb3704e0494be8081e578932b schema:name pubmed_id
107 schema:value 1974686
108 rdf:type schema:PropertyValue
109 N27662ab6e2be4626a463b041c48970ba schema:affiliation grid-institutes:grid.477310.6
110 schema:familyName Tan
111 schema:givenName Y.
112 rdf:type schema:Person
113 N54184c1bc56b4029a21b190e18564404 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Bronchodilator Agents
115 rdf:type schema:DefinedTerm
116 N5a035d87f6f74290acbbbb72475b5889 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Formoterol Fumarate
118 rdf:type schema:DefinedTerm
119 N68a913c0925f4e899aad5deb9ed3a543 schema:volumeNumber 168
120 rdf:type schema:PublicationVolume
121 N6bfe1bea8b424ec29a0c5fd0f6850462 rdf:first sg:person.01270703304.03
122 rdf:rest rdf:nil
123 N6e5f46aa24484b47b63eb2c2cb0ecbd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Male
125 rdf:type schema:DefinedTerm
126 N74d03ab14f5c495a85cd2f1672d5a035 rdf:first sg:person.01217467714.63
127 rdf:rest N09dc351f08174d029324cd642074155f
128 N7be96e42e4524028a6480acb5acb59c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Long-Term Care
130 rdf:type schema:DefinedTerm
131 N80b566a240ea47089a27f0ead5882945 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Forced Expiratory Volume
133 rdf:type schema:DefinedTerm
134 N8179a221a3564f21a0c3e216a368edc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Randomized Controlled Trials as Topic
136 rdf:type schema:DefinedTerm
137 N878f486c0851413eaaeb22e611a1bebb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Delayed-Action Preparations
139 rdf:type schema:DefinedTerm
140 N8820be068f384bdf87e4471ff889afd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Drug Administration Schedule
142 rdf:type schema:DefinedTerm
143 N8b3be7957f6b4e79a3ba2f69b1d59213 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Administration, Inhalation
145 rdf:type schema:DefinedTerm
146 N8ecfebae22db46fcacc3e4673c188c84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Adolescent
148 rdf:type schema:DefinedTerm
149 N9bc84b0cdcf74b18a7aff5a741d67959 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Adrenergic beta-Agonists
151 rdf:type schema:DefinedTerm
152 N9d5eb31faf0346528ef5cc49aaa1a7a2 schema:issueNumber Suppl 1
153 rdf:type schema:PublicationIssue
154 Na0133665a52740479c307d44f30bcec2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Humans
156 rdf:type schema:DefinedTerm
157 Na30d297ac51f44c0a86866632607bf19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Multicenter Studies as Topic
159 rdf:type schema:DefinedTerm
160 Na3378954ad8d43dab0e38fb1cd1fb262 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Lung Diseases, Obstructive
162 rdf:type schema:DefinedTerm
163 Nadd555e2149540eb82bde041b795025f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Ethanolamines
165 rdf:type schema:DefinedTerm
166 Nbd2bc7bc603b4feab3b2b91ab04422e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Asthma
168 rdf:type schema:DefinedTerm
169 Nbd6bb6a01c8e47bf8a3866f08dfab8c9 schema:name Springer Nature - SN SciGraph project
170 rdf:type schema:Organization
171 Nbf56ef3f24c84aea8b2599acb1124685 rdf:first sg:person.01141121675.44
172 rdf:rest Nfcffa9dddd80428fb51c3ba41afd29f6
173 Nc92c7954e9034fe6b023f4d20878e9ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Middle Aged
175 rdf:type schema:DefinedTerm
176 Nd5cc577ca5814c6fb8602cf6b37c9cd5 schema:name dimensions_id
177 schema:value pub.1012000274
178 rdf:type schema:PropertyValue
179 Nd61324b3bad14377900ae4350298ece4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Albuterol
181 rdf:type schema:DefinedTerm
182 Nd665c93701df4a85874fd61670c37d94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Airway Resistance
184 rdf:type schema:DefinedTerm
185 Nd6e0b80b778b4266bb822773fa15460d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Adult
187 rdf:type schema:DefinedTerm
188 Nde76a0531cd24a9b9bbbea222cfab716 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Aged
190 rdf:type schema:DefinedTerm
191 Nec05093ae9aa49a2b1427f82cf816a24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Peak Expiratory Flow Rate
193 rdf:type schema:DefinedTerm
194 Neea471bfba7746308bd247873ebdb264 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Female
196 rdf:type schema:DefinedTerm
197 Nfcffa9dddd80428fb51c3ba41afd29f6 rdf:first sg:person.0610312214.35
198 rdf:rest N01ee4be6ada9438ba98c323f7df284af
199 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
200 schema:name Medical and Health Sciences
201 rdf:type schema:DefinedTerm
202 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
203 schema:name Pharmacology and Pharmaceutical Sciences
204 rdf:type schema:DefinedTerm
205 sg:journal.1054004 schema:issn 0341-2040
206 1432-1750
207 schema:name Lung
208 schema:publisher Springer Nature
209 rdf:type schema:Periodical
210 sg:person.01141121675.44 schema:affiliation grid-institutes:grid.477310.6
211 schema:familyName Greefhorst
212 schema:givenName A.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141121675.44
214 rdf:type schema:Person
215 sg:person.01217467714.63 schema:affiliation grid-institutes:grid.477310.6
216 schema:familyName Hekking
217 schema:givenName P. R.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217467714.63
219 rdf:type schema:Person
220 sg:person.01270703304.03 schema:affiliation grid-institutes:grid.477310.6
221 schema:familyName Zweers
222 schema:givenName P.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270703304.03
224 rdf:type schema:Person
225 sg:person.0610312214.35 schema:affiliation grid-institutes:grid.477310.6
226 schema:familyName Prins
227 schema:givenName J.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610312214.35
229 rdf:type schema:Person
230 sg:person.07672177314.29 schema:affiliation grid-institutes:grid.477310.6
231 schema:familyName Maesen
232 schema:givenName F.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07672177314.29
234 rdf:type schema:Person
235 grid-institutes:grid.477310.6 schema:alternateName Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands
236 schema:name Havenziekenhuis, Haringvliet 2, 3011 TD, Rotterdam, The Netherlands
237 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...